Article

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Blood (Impact Factor: 9.78). 04/2010; 116(5):702-10. DOI: 10.1182/blood-2010-02-268953
Source: PubMed

ABSTRACT Recent studies of WT1 mutations in acute myeloid leukemia (AML) mostly report an association with unfavorable clinical outcome. We screened 842 patients treated on 3 consecutive pediatric AML trials for WT1 zinc-finger mutations. Eighty-five mutations were detected in 70 of 842 patients (8.3%). Mutations occurred predominantly in exon 7 (n = 74) but were also found in exons 8 (n = 5) and 9 (n = 6). Normal karyotype was observed in 35.3% of WT1(mut) patients, whereas 27.5% WT1(mut) patients harbored favorable risk cytogenetics. Patients with or without mutations had similar rates of complete remission after one course of induction chemotherapy. Overall survival (OS) for patients with WT1 mutations was 41% versus 54% for those without mutations (P = .016). Corresponding event-free survival (EFS) was also significantly worse for those with WT1 mutations (28% vs 42%; P = .01). However, FLT3/ITD was present in 36% of the WT1(mut) cohort; WT1(mut) patients without FLT3/ITD had similar OS (56% vs 56%, respectively; P = .8) and EFS (35% and 44%, respectively; P = .34) to patients who were wild type for both mutations. In current risk stratification schemes incorporating cytogenetics and FLT3/ITD status, the presence of WT1 mutations has no independent prognostic significance in predicting outcome in pediatric AML. The clinical trials are registered at www.clinicaltrials.gov as #NCT00002798 and #NCT00070174.

Download full-text

Full-text

Available from: Robert B Gerbing, Dec 19, 2014
0 Followers
 · 
168 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although acute myeloid leukaemia (AML) has long been recognized for its morphological and cytogenetic heterogeneity, recent high-resolution genomic profiling has demonstrated a complexity even greater than previously imagined. This complexity can be seen in the number and diversity of genetic alterations, epigenetic modifications, and characteristics of the leukaemic stem cells. The broad range of abnormalities across different AML subtypes suggests that improvements in clinical outcome will require the development of targeted therapies for each subtype of disease and the design of novel clinical trials to test these strategies. It is highly unlikely that further gains in long-term survival rates will be possible by mere intensification of conventional chemotherapy. In this review, we summarize recent studies that provide new insight into the genetics and biology of AML, discuss risk stratification and therapy for this disease, and profile some of the therapeutic agents currently under investigation.
    British Journal of Haematology 09/2012; 159(3):259-76. DOI:10.1111/bjh.12040 · 4.96 Impact Factor
  • Source
    Acute Leukemia - The Scientist's Perspective and Challenge, 12/2011; , ISBN: 978-953-307-553-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute myeloid leukemia (AML) is a family of hematopoietic neoplasms characterized by proliferation of myeloid-lineage blast cells in the bone marrow, peripheral blood, and/or extramedullary sites. Appropriate classification and subclassification of these neoplasms is necessary to ensure appropriate therapy. This classification is increasingly based upon the underlying genetic abnormalities of these diseases, and evaluation for these abnormalities has become standard of care in the diagnosis and treatment of acute leukemias. The current WHO classification incorporates a combination of clinical features, morphologic features, immunophenotype, karyotype, and molecular testing to precisely subclassify these diseases [1]. This is considered a work in progress, and, as more abnormalities are identified, they will be incorporated into novel diagnostic and prognostic subgroups. In addition, at least some of these mutations are being incorporated into minimal residual disease testing and some are targeted for directed therapy.